Johnson & Johnson $JNJ Stock: Cullen Capital Management LLC Cuts Holdings

by · The Markets Daily

Cullen Capital Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 6.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,032,593 shares of the company’s stock after selling 66,484 shares during the quarter. Johnson & Johnson comprises approximately 2.7% of Cullen Capital Management LLC’s investment portfolio, making the stock its 3rd largest holding. Cullen Capital Management LLC’s holdings in Johnson & Johnson were worth $273,369,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Ironwood Investment Counsel LLC lifted its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Ironwood Investment Counsel LLC now owns 64,254 shares of the company’s stock valued at $17,011,000 after buying an additional 459 shares during the period. Godfrey Financial Associates Inc. grew its holdings in Johnson & Johnson by 3.0% during the third quarter. Godfrey Financial Associates Inc. now owns 4,696 shares of the company’s stock worth $1,243,000 after acquiring an additional 136 shares during the period. Vawter Financial Ltd. acquired a new stake in Johnson & Johnson during the third quarter worth about $618,000. Edgestream Partners L.P. acquired a new stake in Johnson & Johnson during the third quarter worth about $821,000. Finally, Banco Santander S.A. raised its position in Johnson & Johnson by 101.3% during the third quarter. Banco Santander S.A. now owns 79,610 shares of the company’s stock valued at $21,076,000 after acquiring an additional 40,053 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson News Roundup

Investors following JNJ have been watching these news items:

  • Positive Sentiment: J&J will pay $2.2 billion upfront for Ollin, with up to about $1.1 billion in additional regulatory and commercial milestone payments. The acquisition adds OLN324, a late-stage antibody being developed for wet age-related macular degeneration and diabetic macular edema, and could complement J&J’s existing eye-care business. J&J bets $2.2B on Ollin’s vision loss drug
  • Positive Sentiment: Blackstone Life Sciences will provide $750 million to fund OLN324’s Phase 3 program, helping support development of the drug while sharing its funding burden. Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
  • Neutral Sentiment: OLN324 is still investigational, so its commercial prospects depend on successful trials, regulatory approval and uptake. The retinal-disease market is crowded and competitive, which could limit eventual returns on the acquisition. J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. UBS Group set a $270.00 price target on Johnson & Johnson in a report on Wednesday, October 14th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Citigroup raised their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Finally, Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $275.92.

View Our Latest Stock Analysis on JNJ

Johnson & Johnson Trading Down 1.1%

JNJ stock opened at $282.62 on Tuesday. The company’s 50-day simple moving average is $267.12 and its 200-day simple moving average is $250.12. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $195.90 and a 52-week high of $290.25. The firm has a market cap of $680.36 billion, a P/E ratio of 42.82, a PEG ratio of 2.80 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. During the same period last year, the firm earned $2.80 EPS. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Read More